I view an interim result that can’t move forward as designed as a fail.
Additional work required to address this (I am guessing) was not economically viable hence the trial halt.
I agree the release did not use the word “fail”, that’s just how I read it.
I agree I could be wrong and maybe the trial was never worthwhile due to the commons list ending next year.
I remain invested and retain hope.
Ann: European RAT Clinical Trial Halted to Refocus Initiatives, page-140
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.003(10.3%) |
Mkt cap ! $64.73M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.0¢ | 2.6¢ | $209.8K | 7.543M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 592714 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 269442 | 1 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |